May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Aldose Reductase Inhibitor Attenuates Leukocyte-Endothelial Interaction in Experimental Diabetic Retina in vivo
Author Affiliations & Notes
  • T. Hattori
    Ophthalmology, Nagoya City Univ Grad Sch Med, Nagoya, Japan
  • A. Matsubara
    Ophthalmology, Nagoya City Univ Grad Sch Med, Nagoya, Japan
  • K. Taniguchi
    Ophthalmology, Nagoya City Univ Grad Sch Med, Nagoya, Japan
  • Y. Ogura
    Ophthalmology, Nagoya City Univ Grad Sch Med, Nagoya, Japan
  • Footnotes
    Commercial Relationships  T. Hattori, None; A. Matsubara, None; K. Taniguchi, None; Y. Ogura, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4917. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Hattori, A. Matsubara, K. Taniguchi, Y. Ogura; Aldose Reductase Inhibitor Attenuates Leukocyte-Endothelial Interaction in Experimental Diabetic Retina in vivo. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4917.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Increased activity of polyol pathway has been implicated in the pathogenesis of diabetic retinopathy. Aldose reductase inhibitor is expected to prevent or improve diabetic retinopathy. Recently, it has been reported that aldose reductase inhibitor (fidarestat) prevent retinal oxidative stress and vascular endothelial growth factor overexpression in diabetic rats. Moreover, increased leukocyte entrapment has been suggested to be involved in blood flow disturbances in the early diabetic retina. In this study, we investigate the effect of fidarestat on leukocyte-endothelial interaction in experimental diabetic retina in vivo.

Methods: : Diabetes was induced in male Long-Evans rats by intraperitoneal injection of streptozotocin (STZ: 75mg/kg). Fidarestat (4 or 16mg/kg/day) was administered orally during 4-week diabetic period. Retinal sorbitol and fructose concentrations were measured by LC/MS/MS method. Accumulated leukocytes in the retinal microcirculation were quantitatively evaluated in vivo with acridine orange digital fluorography.

Results: : Retinal sorbitol and fructose concentrations were approximately 3-fold higher in untreated diabetic rats than in the control rats. High dose of fidarestat completely normalized retinal sorbitol concentration, whereas retinal fructose concentration was reduced by 80%. The number of leukocytes trapped in the retinal microcirculation of diabetic rats (9.8 ± 3.9 cells/mm2) was significantly increased, compared with nondiabetic control rats (3.4 ± 2.1 cells/mm2; P < 0.01). Oral administration of fidarestat significantly decreased the number of leukocytes trapped in the retinal microcirculation of diabetic rats (6.1 ± 3.5 and 5.2 ± 3.2 cells/mm2 with low dose and high dose fidarestat, respectively; P < 0.01).

Conclusions: : Oral administration of fidarestat attenuated the increase of leukocyte entrapment in the retinal microcirculation during the period of early diabetes. These results suggest a therapeutic potential of fidarestat on diabetic retinopathy.

Keywords: diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×